{
  "title": "Paper_1215",
  "abstract": "pmc Pharmaceuticals (Basel) Pharmaceuticals (Basel) 2102 pharmaceuticals pharmaceuticals Pharmaceuticals 1424-8247 Multidisciplinary Digital Publishing Institute  (MDPI) PMC12472517 PMC12472517.1 12472517 12472517 41011266 10.3390/ph18091397 pharmaceuticals-18-01397 1 Viewpoint PROTACs and Glues: Striking Perspectives for Engineering Cancer Therapy À La Carte Ferrero Jean-Marc 1 https://orcid.org/0000-0002-1802-118X Gal Jocelyn 2 https://orcid.org/0000-0002-1025-3429 Mograbi Baharia 3 Milano Gérard 4 * Bono Alessia Academic Editor Lauria Antonino Academic Editor 1 jean-marc.ferrero@nice.unicancer.fr 2 jocelyn.gal@nice.unicancer.fr 3 baharia.mograbi@univ-cotedazur.fr 4 * gerard.milano@nice.unicancer.fr 17 9 2025 9 2025 18 9 497460 1397 24 7 2025 09 9 2025 15 9 2025 17 09 2025 27 09 2025 29 09 2025 © 2025 by the authors. 2025 https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/ PROTACs are bifunctional small molecules that simultaneously bind a target protein and a component of the ubiquitin–proteasome system, thereby inducing selective degradation of the target. They represent a class of compounds capable of achieving the complete elimination of disease-relevant proteins. Molecular glues, by contrast, enhance existing surface complementarity between an E3 ligase and a target protein, promoting its ubiquitination and subsequent degradation. Both approaches are at the forefront of current efforts to overcome the long-standing challenge of undruggable tumor targets. In this context, AI-based strategies offer a powerful means to accelerate the discovery, optimization, and production of highly selective protein binders, streamlining access to potent degraders and maximizing therapeutic potential. These capabilities open new horizons for targeting a wide spectrum of previously inaccessible molecular pathways involved in cancer progression. Altogether, these advances position PROTACs and molecular glues as transformative agents for personalized oncology, particularly within the emerging paradigm of molecular tumor boards, where tailored therapeutic decisions and tumor-adapted drugs could be made rapidly accessible for a given patient. PROTACs molecular glue artificial intelligence anticancer drug personalized therapy French national research agency ANR-23-IAHU-007 IDEX reference ANR-15-IDEX-01 “Investments for the Future” LABEX SIGNALIFE ANR-11-LABX-0028–01 This work was supported by the French national research agency (“IHU RespirERA” France 2030 program # ANR-23-IAHU-007); IDEX reference (IDEX UCA Jedi ANR-15-IDEX-01); and “Investments for the Future” LABEX SIGNALIFE (program reference # ANR-11-LABX-0028–01). pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes 1. General Principles 1.1. Definition of Degraders and Glues The term PROTACs (proteolysis-targeting chimeras) was first coined by Sakamoto and coworkers in 2001 [ 1 2 1 2 3 2 3 3 3 3 The integration of PROTACs as molecules that promote targeted protein degradation constitutes a promising advance in the fight against cancer. Interestingly, the molecular design of PROTACs enables the integration of binders for ligases and targets; however, this must be viewed against the background of certain challenges associated with the chemical properties of these binders [ 4 5 Basically, the discovery of molecular glues is linked to the elucidation of the mechanism of action of thalidomide. Several decades after withdrawal of this drug from the market due to teratogenicity, thalidomide was reported in 2010 to bind to the substrate receptor protein of a specific E 3 6 3 7 8 9 1.2. PROTACs Versus Glues With PROTACs in one hand and molecular glues in the other, it is interesting to compare the respective advantages and limitations of these two relatively similar approaches as therapeutic tools for degrading targeted proteins [ 10 11 12 13 3 3 14 10 Another point of comparison lies in the respective constraints of development, with a relatively high complexity in PROTACs design, due to the simultaneous binding of the drug to the targeted protein and the ligase. In this respect, out-target effects of PROTACs have been described and are still not fully understood [ 11 15 4 Table 1 2. Degraders and Glues in the Context of Personalized Cancer Therapy 2.1. Current Status of Personalized Therapy After briefly covering the main aspects of PROTACs and glues, the next step is to consider this relatively new family of anticancer agents in the context of personalized therapy. Continuous innovation in genomics and the increasing understanding of the cancer genome have enabled precision oncology to be applied to a broad spectrum of cancer types [ 16 17 18 19 20 21 22 23 2.2. Perspectives Offered by PROTACs and Glues The domain of PROTACs and glues is potentially well-suited to addressing this unmet need, and drugs representative of this therapeutic class are nearing market release [ 24 25 26 27 28 22 29 30 29 31 32 33 34 35 36 37 38 39 The World Wide Innovative Network (WIN) consortium in personalized cancer medicine provides an ongoing vision for innovation, collaboration and global impact in precision oncology [ 40 Figure 1 41 42 Figure 1 36 43 44 36 45 46 47 48 49 50 26 51 3. Conclusions and Perspectives Arvinas and Pfizer were able to successfully conduct and complete the clinical development of Vepdegestrant through the trial VERITAC-2 [ 52 53 3 54 Figure 1 3 55 56 57 Acknowledgments We apologize to authors whose work could not be cited owing to space limitations. Disclaimer/Publisher’s Note: Author Contributions G.M., J.G., J.-M.F. and B.M. participated in writing and critically revising the important intellectual content of this manuscript. All authors have read and agreed to the published version of the manuscript. Data Availability Statement Not applicable. There is no data or materials involved in this review. Conflicts of Interest The authors declare no conflicts of interest. References 1. Sakamoto K.M. Kim K.B. Kumagai A. Mercurio F. Crews C.M. Deshaies R.J. Protacs: Chimeric Molecules That Target Proteins to the Skp1-Cullin-F Box Complex for Ubiquitination and Degradation Proc. Natl. Acad. Sci. USA 2001 98 8554 8559 10.1073/pnas.141230798 11438690 PMC37474 2. Bard J.A.M. Goodall E.A. Greene E.R. Jonsson E. Dong K.C. Martin Structure and Function of the 26s Proteasome Annu. Rev. Biochem. 2018 87 697 724 10.1146/annurev-biochem-062917-011931 29652515 PMC6422034 3. London N. Covalent Proximity Inducers Chem. Rev. 2025 125 326 368 10.1021/acs.chemrev.4c00570 39692621 PMC11719315 4. Tsai J.M. Nowak R.P. Ebert B.L. Fischer E.S. Targeted Protein Degradation: From Mechanisms to Clinic Nat. Rev. Mol. Cell Biol. 2024 25 740 757 10.1038/s41580-024-00729-9 38684868 5. Békés M. Langley D.R. Crews C.M. Protac Targeted Protein Degraders: The Past Is Prologue Nat. Rev. Drug Discov. 2022 21 181 200 10.1038/s41573-021-00371-6 35042991 PMC8765495 6. Ito T. Ando H. Suzuki T. Ogura T. Hotta K. Imamura Y. Yamaguchi Y. Handa Identification of a Primary Target of Thalidomide Teratogenicity Science 2010 327 1345 1350 10.1126/science.1177319 20223979 7. Oleinikovas V. Gainza P. Ryckmans T. Fasching B. Thomä N.H. From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation Annu. Rev. Pharmacol. Toxicol. 2024 64 291 312 10.1146/annurev-pharmtox-022123-104147 37585660 8. Holstein S.A. McCarthy P.L. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience Drugs 2017 77 505 520 10.1007/s40265-017-0689-1 28205024 PMC5705939 9. Matyskiela M.E. Lu G. Ito T. Pagarigan B. Lu C.C. Miller K. Fang W. Wang N.Y. Nguyen D. Houston J. A Novel Cereblon Modulator Recruits GSPT1 to the CRL4(CRBN) Ubiquitin Ligase Nature 2016 535 252 257 10.1038/nature18611 27338790 10. Sasso J.M. Tenchov R. Wang D. Johnson L.S. Wang X. Zhou Q.A. Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic Biochemistry 2023 62 601 623 10.1021/acs.biochem.2c00245 35856839 PMC9910052 11. Liu Z. Hu M. Yang Y. Du C. Zhou H. Liu C. Chen Y. Fan L. Ma H. Gong Y. An Overview of PROTACs: A Promising Drug Discovery Paradigm Mol. Biomed. 2022 3 46 10.1186/s43556-022-00112-0 36536188 PMC9763089 12. Pike A. Williamson B. Harlfinger S. Martin S. McGinnity D.F. Optimising Proteolysis-Targeting Chimeras (Protacs) for Oral Drug Delivery: A Drug Metabolism and Pharmacokinetics Perspective Drug Discov. Today 2020 25 1793 1800 10.1016/j.drudis.2020.07.013 32693163 13. Verma R. Mohl D. Deshaies R.J. Harnessing the Power of Proteolysis for Targeted Protein Inactivation Mol. Cell 2020 77 446 460 10.1016/j.molcel.2020.01.010 32004468 14. Zhang L. Riley-Gillis B. Vijay P. Shen Y. Acquired Resistance to Bet-Protacs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes Mol. Cancer Ther. 2019 18 1302 1311 10.1158/1535-7163.MCT-18-1129 31064868 15. Gao H. Sun X. Rao Y. Protac Technology: Opportunities and Challenges ACS Med. Chem. Lett. 2020 11 237 240 10.1021/acsmedchemlett.9b00597 32184950 PMC7073876 16. Heo Y. Kim W.-J. Cho Y.-J. Jung J.-W. Kim N.-S. Choi I.-Y. Advances in Cancer Genomics and Precision Oncology Genes Genom. 2025 47 399 416 10.1007/s13258-024-01614-7 39849190 17. Andre F.T. Kamal M. Mosele F. Arnedos M. Dalenc F. Sablin M.P. Campone M. Bonnefoi H. Lefeuvre-Plesse C. Jacot W. Genomics to Select Treatment for Patients with Metastatic Breast Cancer Nature 2022 610 343 348 10.1038/s41586-022-05068-3 36071165 18. Tourneau L. Delord J.P. Gonçalves A. Gavoille C. Dubot C. Isambert N. Campone M. Trédan O. Massiani M.A. Mauborgne C. Molecularly Targeted Therapy Based on Tumour Molecular Profiling Versus Conventional Therapy for Advanced Cancer (Shiva): A Multicentre, Open-Label, Proof-of-Concept, Randomised, Controlled Phase 2 Trial Lancet Oncol. 2015 16 1324 1334 10.1016/S1470-2045(15)00188-6 26342236 19. Heath E. Dyson G. Ribeiro J.R. Xiu J. Poorman K. Mamdani H. Al-Hallak M.N. Shields A.F. Elayoubi J.A. Winer I.S. Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Cancer Res. Commun. 2024 4 2598 2609 10.1158/2767-9764.CRC-24-0321 39172022 PMC11450693 20. Weinberg R.A. It Took a Long, Long Time: Ras and the Race to Cure Cancer Cell 2024 187 1574 1577 10.1016/j.cell.2024.02.042 38552606 21. Oren M. Prives C. P53: A Tale of Complexity and Context Cell 2024 187 1569 1573 10.1016/j.cell.2024.02.043 38552605 22. Yang Y. Zhu G. Zeng H. Fan Y. Guo F. Xu D. Wang B. Chen D. Ge G. Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer Int. J. Biol. Sci. 2023 19 3360 3382 10.7150/ijbs.83026 37496997 PMC10367563 23. Choi Y.H. Chang J.-E. Targeted Therapy for Cancers: From Ongoing Clinical Trials to Fda-Approved Drugs Int. J. Mol. Sci. 2023 24 13618 10.3390/ijms241713618 37686423 PMC10487969 24. Rathkopf D.E. Patel M.R. Choudhury A.D. Rasco D. Lakhani N. Hawley J.E. Srinivas S. Aparicio A. Narayan V. Runcie K.D. Safety and Clinical Activity of Bms-986365 (Cc-94676), a Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer Ann. Oncol. 2025 36 76 88 10.1016/j.annonc.2024.09.005 39293515 PMC12094577 25. Hamilton E.P. Ma C. De Laurentiis M. Iwata H. Hurvitz S.A. Wander S.A. Danso M. Lu D.R. Smith J.P. Liu Y. Veritac-2: A Phase Iii Study of Vepdegestrant, a Protac Er Degrader, Versus Fulvestrant in Er+/Her2- Advanced Breast Cancer Future Oncol. 2024 20 2447 2455 10.1080/14796694.2024.2377530 39072356 PMC11524203 26. Xinyi L. Pu W. Zheng Q. Ai M. Chen S. Peng Y. Proteolysis-Targeting Chimeras (Protacs) in Cancer Therapy Mol. Cancer 2022 21 99 10.1186/s12943-021-01434-3 35410300 PMC8996410 27. Albanese K.I. Barbe S. Tagami S. Woolfson D.N. Schiex T. Computational Protein Design Nat. Rev. Methods Primers 2025 5 13 10.1038/s43586-025-00383-1 28. Liu F. Cai Q. Deng L. Ouyang Q. Zhang X.H. Zheng J. Invasion and Metastasis in Cancer: Molecular Insights and Therapeutic Targets Signal Transduct. Target. Ther. 2025 10 57 10.1038/s41392-025-02148-4 39979279 PMC11842613 29. Jia X. Tang B. Ma C. Fang X. Jin X. Niu Z. Han X. In Silico Modeling of Targeted Protein Degradation Eur. J. Med. Chem. 2025 289 117432 10.1016/j.ejmech.2025.117432 40015161 30. Abramson J. Adler J. Dunger J. Evans R. Green T. Pritzel A. Ronneberger O. Willmore L. Ballard A.J. Bambrick J. Accurate Structure Prediction of Biomolecular Interactions with Alphafold 3 Nature 2024 630 493 500 10.1038/s41586-024-07487-w 38718835 PMC11168924 31. Maneiro M. De Vita E. Conole D. Kounde C.S. Zhang Q. Tate E.W. Protacs, Molecular Glues and Bifunctionals from Bench to Bedside: Unlocking the Clinical Potential of Catalytic Drugs Prog. Med. Chem. 2021 60 67 190 34147206 10.1016/bs.pmch.2021.01.002 32. Petzold G. Gainza P. Annunziato S. Lamberto I. Trenh P. McAllister L. Demarco B. Schwander L. Bunker R.D. Zlotosch M. Mining the Crbn Target Space Redefines Rules for Molecular Glue-Induced Neosubstrate Recognition Science 2025 389 eadt6736 10.1126/science.adt6736 40608931 33. Gou X. Tan S.K. Mann S.I. Yang H. Zhong X. Gazgalis D. Valdiviezo J. Jo H. Wu Y. Diolaiti M.E. De Novo Design of Drug-Binding Proteins with Predictable Binding Energy and Specificity Science 2024 384 106 112 10.1126/science.adl5364 38574125 PMC11290694 34. Marchand A. Buckley S. Schneuing A. Pacesa M. Elia M. Gainza P. Elizarova E. Neeser R.M. Lee P.-W. Reymond L. Targeting Protein–Ligand Neosurfaces with a Generalizable Deep Learning Tool Nature 2025 639 522 531 10.1038/s41586-024-08435-4 39814890 PMC11903328 35. Gainza P. Wehrle S. Van Hall-Beauvais A. Marchand A. Scheck A. Harteveld Z. Buckley S. Ni D. Tan S. Sverrisson F. De Novo Design of Protein Interactions with Learned Surface Fingerprints Nature 2023 617 176 184 10.1038/s41586-023-05993-x 37100904 PMC10131520 36. Ren F. Ding X. Zheng M. Korzinkin M. Cai X. Zhu W. Mantsyzov A. Aliper A. Aladinskiy V. Cao Z. Alphafold Accelerates Artificial Intelligence Powered Drug Discovery: Efficient Discovery of a Novel Cdk20 Small Molecule Inhibitor Chem. Sci. 2023 14 1443 1452 10.1039/D2SC05709C 36794205 PMC9906638 37. Kamya P. Ozerov I.V. Pun F.W. Tretina K. Fokina T. Chen S. Naumov V. Long X. Lin S. Korzinkin M. Pandaomics: An Ai-Driven Platform for Therapeutic Target and Biomarker Discovery J. Chem. Inf. Model. 2024 64 3961 3969 10.1021/acs.jcim.3c01619 38404138 PMC11134400 38. Ivanenkov Y.A. Polykovskiy D. Bezrukov D. Zagribelnyy B. Aladinskiy V. Kamya P. Aliper A. Ren F. Zhavoronkov A. Chemistry42: An Ai-Driven Platform for Molecular Design and Optimization J. Chem. Inf. Model. 2023 63 695 701 10.1021/acs.jcim.2c01191 36728505 PMC9930109 39. Shen C. Song J. Hsieh C.Y. Cao D. Kang Y. Ye W. Wu Z. Wang J. Zhang O. Zhang X. Drugflow: An Ai-Driven One-Stop Platform for Innovative Drug Discovery J. Chem. Inf. Model. 2024 64 5381 5391 10.1021/acs.jcim.4c00621 38920405 40. El-Deiry W.S. Bresson C. Wunder F. Carneiro B.A. Dizon D.S. Warner J.L. Graff S.L. Azzoli C.G. Wong E.T. Cheng L. Worldwide Innovative Network (Win) Consortium in Personalized Cancer Medicine: Bringing Next-Generation Precision Oncology to Patients Oncotarget 2025 16 140 162 10.18632/oncotarget.28703 40073368 PMC11907938 41. Westphalen C. Benedikt C. Bielo L.B. Aftimos P. Beltran H. Benary M. Chakravarty D. Collienne M. Dienstmann R. El Helali A. Esmo Precision Oncology Working Group Recommendations on the Structure and Quality Indicators for Molecular Tumour Boards in Clinical Practice Ann. Oncol. 2025 36 614 625 10.1016/j.annonc.2025.02.009 40194904 42. Casolino R. Beer P.A. Chakravarty D. Davis M.B. Malapelle U. Mazzarella L. Normanno N. Pauli C. Subbiah V. Turnbull C. Interpreting and Integrating Genomic Tests Results in Clinical Cancer Care: Overview and Practical Guidance CA Cancer J. Clin. 2024 74 264 285 10.3322/caac.21825 38174605 43. Lu H. Zhao B. Zhang J. Huang R. Wang Z. Xu H. Huang B. Does Delayed Initiation of Adjuvant Chemotherapy Following the Curative Resection Affect the Survival Outcome of Gastric Cancer Patients: A Systematic Review and Meta-Analysis Eur. J. Surg. Oncol. 2020 46 1103 1110 10.1016/j.ejso.2020.01.013 31948838 44. Turner M.C. Farrow N.E. Rhodin K.E. Sun Z. Adam M.A. Mantyh C.R. Migaly J. Delay in Adjuvant Chemotherapy and Survival Advantage in Stage Iii Colon Cancer J. Am. Coll. Surg. 2018 226 670 678 10.1016/j.jamcollsurg.2017.12.048 29378259 45. Jiao D. Liu A. Wu K. Tumor Organoids: Applications in Cancer Modeling and Potentials in Precision Medicine J. Hematol. Oncol. 2022 15 58 10.1186/s13045-022-01278-4 35551634 PMC9103066 46. Fritsch E.F. Ott P.A. Personalized Cancer Vaccines Directed against Tumor Mutations: Building Evidence from Mice to Humans Cancer Res. 2024 84 953 955 10.1158/0008-5472.CAN-24-0565 38558128 47. Le Tourneau C. Rolland F. Capitain O. Cassier P.A. Fumet J.D. Salas S. Daste A. Manso L. Bermejo-Perez M.-J. Casado A. Randomized Phase Ii Trial Evaluating the Combination of Tg4001, an Hpv16 Therapeutic Vaccine, and Avelumab (Ave) in Patients (Pts) with Immunotherapy-Naïve Recurrent and/or Metastatic (R/M) Hpv16-Positive Cervical or Anogenital Cancer J. Clin. Oncol. 2025 43 (Suppl. 16) 2638 10.1200/JCO.2025.43.16_suppl.2638 48. Sellars M.L.C. Wu C.J. Fritsch E.F. Cancer Vaccines: Building a Bridge over Troubled Waters Cell 2022 185 2770 2788 10.1016/j.cell.2022.06.035 35835100 PMC9555301 49. Maalej K.M. Merhi M. Inchakalody V.P. Mestiri S. Alam M. Maccalli C. Cherif H. Uddin S. Steinhoff M. Marincola F.M. Car-Cell Therapy in the Era of Solid Tumor Treatment: Current Challenges and Emerging Therapeutic Advances Mol. Cancer 2023 22 20 10.1186/s12943-023-01723-z 36717905 PMC9885707 50. Hunter T.L. Bao Y. Zhang Y. Matsuda D. Riener R. Wang A. Li J.J. Soldevila F. Chu D.S.H. Nguyen D.P. In Vivo Car T Cell Generation to Treat Cancer and Autoimmune Disease Science 2025 388 1311 1317 10.1126/science.ads8473 40536974 51. Arnold C. Autoimmune Disease Is the Next Frontier for Car T Cell Therapy Nat. Med. 2024 30 6 9 10.1038/s41591-023-02716-7 38212433 52. Campone M. De Laurentiis M. Jhaveri K. Hu X. Ladoire S. Patsouris A. Zamagni C. Cui J. Cazzaniga M. Cil T. Vepdegestrant, a Protac Estrogen Receptor Degrader, in Advanced Breast Cancer N. Engl. J. Med. 2025 393 556 568 10.1056/NEJMoa2505725 40454645 53. Antonarelli G. Perez-Garcia J.M. Gion M. Rugo H. Schmid P. Bardia A. Hurvitz S. Harbeck N. Tolaney S.M. Curigliano G. Redefining Clinical Trial Strategic Design to Support Drug Approval in Medical Oncology Ann. Oncol. 2025 36 645 650 10.1016/j.annonc.2025.03.005 40086733 54. Hinterndorfer M. Spiteri V.A. Ciulli A. Winter G.E. Targeted Protein Degradation for Cancer Therapy Nat. Rev. Cancer 2025 25 493 516 10.1038/s41568-025-00817-8 40281114 55. Kang C. Xu W. Leveraging Structural and Computational Biology for Molecular Glue Discovery ACS Publications Washington, DC, USA 2025 10.1021/acs.jmedchem.5c00076 39854250 56. Oualikene-Gonin W. Jaulent M.C. Thierry J.P. Oliveira-Martins S. Belgodere L. Maison P. Ankri J. Scientific Advisory Board of ANSM Artificial Intelligence Integration in the Drug Lifecycle and in Regulatory Science: Policy Implications, Challenges and Opportunities Front. Pharmacol. 2024 15 1437167 10.3389/fphar.2024.1437167 39156111 PMC11327028 57. The Lancet Oncology Cancer Drug Discovery at Warp Speed: Can Ai Deliver? Lancet Oncol. 2025 26 981 10.1016/S1470-2045(25)00431-0 40744028 Figure 1 A proposal for a descriptive approach in the dynamics of molecular tumor board management by applying an ultra-personalized cancer medicine based on PROTACs and glues and guided by AI. pharmaceuticals-18-01397-t001_Table 1 Table 1 Respective characteristics and properties of PROTACs and glues. Criteria PROTACs Glues Conception Complex Less predictable Mechanism of action Bifunctional Monofunctional Size High (>800 Da) Low (Inf 500 Da) Modularity High Low Targeting capacity Large Restricted Conception Complex Less predictable Pharmacokinetics properties Unfavorable Favorable Oral absorption Erratic Satisfactory CNS penetration Low High Prolonged action High capacity Low capacity ",
  "metadata": {
    "Title of this paper": "Cancer Drug Discovery at Warp Speed: Can Ai Deliver?",
    "Journal it was published in:": "Pharmaceuticals",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472517/"
  }
}